Abstract
Purpose: To estimate parameters for the tumor control probability (TCP) model based on the linear‐quadratic (LQ) cell survival formalism from published clinical data for early stage NSCLC and to investigate potential outcomes of alternate dose fractionation schemes. Method and Materials: A comprehensive literature search was performed to identify studies reporting local control after conventionally fractionated 3DCRT and hypofractionated stereotactic body radiation therapy (SBRT) for T1‐2N0M0 NSCLC. Parameters of the LQ‐based TCP model were estimated by fitting the selected clinical data sets using the maximum likelihood method. Fits were obtained and compared for three versions of the TCP model: without the time effect, with an exponential growth of clonogens, and with delayed onset of clonogen proliferation. Obtained parameter estimates were used to compare different fractionation schemes that take advantage of increase in tumor control as the overall treatment time is reduced. Results: A fit to the exponential growth model was significantly better (p < 0.0001) than a fit to the model with no time effect. Also, the model with delayed onset provided a significantly better fit (p = 0.0142) to the data than the exponential growth model assuming no delay in clonogen repopulation. Parameter estimates for the model with delayed onset were: α = 0.066 Gy−1, α/β = 21.1 Gy, γ = 1.85 Gy/day, Tk = 32.2 days, and k (the number of clonogens) = 6.3. Our analysis of different hypofractionated regiments confirms observations by others and suggests that a moderate reduction in the number of fractions (with the increase in the dose per fraction) may result in better tumor control for the same level of late complications.Conclusion: The derived TCP model parameter estimates may prove useful for biologically based treatment planning of Stage I NSCLC, especially when unconventional fractionation schemes, such as in SBRT, are employed.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.